shRNA and siRNA delivery to the brain

Area of Science:

• Biotechnology
• Molecular Biology
• Neuroscience

Background:

• In vivo RNA interference (RNAi) efficacy is limited by drug delivery challenges.
• Nucleic acid drugs require specific targeting to overcome biological barriers like cell membranes and the blood-brain barrier (BBB).
• Current cell culture delivery methods are often impractical for intravenous RNAi applications in vivo.

Purpose of the Study:

• To develop and evaluate novel in vivo delivery strategies for RNAi therapeutics targeting brain cancer.
• To demonstrate the feasibility of crossing the blood-brain barrier (BBB) for effective RNAi delivery.
• To assess the therapeutic potential of targeted RNAi in an intracranial brain cancer model.

Main Methods:

• Utilized pegylated immunoliposomes (PILs) encapsulating plasmid DNA encoding short hairpin RNA (shRNA) for intravenous delivery.
• Conjugated monoclonal antibodies (MAbs) to PILs for receptor-specific targeting across the BBB.
• Employed mono-biotinylated short interfering RNA (siRNA) combined with MAb-streptavidin conjugates for targeted delivery.

Main Results:

• Weekly intravenous RNAi with PILs achieved a 90% knockdown of the human epidermal growth factor receptor (EGFR).
• This EGFR knockdown resulted in a 90% increase in survival time in mice with intracranial brain cancer.
• Targeted delivery of siRNA using MAb and avidin-biotin technology showed promise for in vivo applications.

Conclusions:

• Targeted delivery systems are essential for effective in vivo RNAi, particularly for brain therapies.
• PILs and antibody-avidin conjugates represent viable strategies for overcoming biological barriers in RNAi drug delivery.
• Intravenous RNAi holds significant therapeutic potential for brain cancers when combined with advanced drug targeting technologies.